Author

Jamal Ghazi Misleh

Observed names: J Misleh, J. G. Misleh, J. Misleh, J.G. Misleh, Jamal G. Misleh, Jamal Misleh

Institution: Medical Oncology Hematology Consultants

Observed institutions: University of Maryland, Baltimore, Christiana Care Health System, University of Maryland Medical System, Hospital of the University of Pennsylvania, Christiana Hospital, Medical Oncology Hematology Consultants, National Cancer Institute, The US Oncology Network, Arizona Oncology, University of Pennsylvania

ORCID: 0009-0004-7747-0948

Observed ORCID: 0009-0004-7747-0948

OpenAlex ID: A5055078293

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

2017 · Jhanelle E. Gray, Rebecca S. Heist, et al. · Clinical Cancer Research · 162

PDF

Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study

2022 · Mazyar Shadman, Ian W Flinn, et al. · The Lancet Haematology · 94

Longitudinal Relationship Between Frailty and Cognition in Patients 50 Years and Older with Breast Cancer

2019 · Allison Magnuson, Lianlian Lei, et al. · Journal of the American Geriatrics Society · 62

Impact of chemotherapy for breast cancer on leukocyte DNA methylation landscape and cognitive function: a prospective study

2019 · Song Yao, Qiang Hu, et al. · Clinical Epigenetics · 62

PDF

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

2021 · Jonathan E. Rosenberg, Karla A. Ballman, et al. · Journal of Clinical Oncology · 58

Post-transplant lymphoproliferative disorder after lung transplantation: A review of 35 cases

2011 · Brandon E. Kremer, Ran Reshef, et al. · The Journal of Heart and Lung Transplantation · 58

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

2023 · Scott A. Tomlins, Nickolay A. Khazanov, et al. · Communications Medicine · 32

PDF

Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma

2014 · T. E. Witzig, M. B. Tomblyn, et al. · Haematologica · 31

A randomized, double‐blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive‐stage small cell lung cancer: Hoosier Cancer Research Network LUN06‐113

2016 · Rachel E. Sanborn, Jyoti D. Patel, et al. · Cancer · 27

PDF

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

2021 · Mazyar Shadman, Ian W. Flinn, et al. · Blood · 25

Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

2025 · Robert L Ferris, Rom S Leidner, et al. · Journal for ImmunoTherapy of Cancer · 16

PDF

Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results

2025 · Mazyar Shadman, John M. Burke, et al. · Blood Advances · 15

PDF

Multidisciplinary Management of Gastric Cancer

2013 · Jamal G. Misleh, Peter Santoro, et al. · Surgical Oncology Clinics of North America · 13

Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit

2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al. · Cancer Research Communications · 12

PDF

Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib.

2021 · Mazyar Shadman, Jeff Porter Sharman, et al. · Journal of Clinical Oncology · 9

Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck.

2025 · Douglas Adkins, Winston Wong, et al. · Journal of Clinical Oncology · 7

PDF

A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC).

2022 · Mark E. Burkard, Meredith McKean, et al. · Journal of Clinical Oncology · 7

Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study

2025 · Jeff Sharman, Aung Tun, et al. · Blood · 6

PDF

868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

2024 · W. Wong, D.R. Adkins, et al. · Annals of Oncology · 6

PDF

A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma

2024 · T. Enzler, A. Nguyen, et al. · European Journal of Cancer · 6

PDF

1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors

2023 · T.U. Marron, J.G. Misleh, et al. · Annals of Oncology · 6

PDF

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 ( NRG1 ) Fusions

2025 · Tejas Patil, Jessica J. Lin, et al. · JCO Precision Oncology · 5

PDF

Abstract CT155: Phase 2 study of sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate (ADC), in patients with pretreated metastatic small-cell lung cancer (mSCLC)

2017 · Jhanelle E. Gray, Rebecca S. Heist, et al. · Cancer Research · 5

646P Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)

2023 · A. Hendifar, D.R. Spigel, et al. · Annals of Oncology · 4

PDF

Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib

2020 · Mazyar Shadman, Jeff P Sharman, et al. · Blood · 4

Works count: 168

Citation count: 760

H-index: 13

I10-index: 14